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Abstract
Background: Identifying genes and pathways associated with diseases such as cancer has been a
subject of considerable research in recent years in the area of bioinformatics and computational
biology. It has been demonstrated that the magnitude of differential expression does not necessarily
indicate biological significance. Even a very small change in the expression of particular gene may
have dramatic physiological consequences if the protein encoded by this gene plays a catalytic role
in a specific cell function. Moreover, highly correlated genes may function together on the same
pathway biologically. Finally, in sparse logistic regression with Lp (p < 1) penalty, the degree of the
sparsity obtained is determined by the value of the regularization parameter. Usually this parameter
must be carefully tuned through cross-validation, which is time consuming.
Results: In this paper, we proposed a simple Bayesian approach to integrate the regularization
parameter out analytically using a new prior. Therefore, there is no longer a need for parameter
selection, as it is eliminated entirely from the model. The proposed algorithm (BLpLog) is typically
two or three orders of magnitude faster than the original algorithm and free from bias in
performance estimation. We also define a novel similarity measure and develop an integrated
algorithm to hunt the regulatory genes with low expression changes but having high correlation
with the selected genes. Pathways of those correlated genes were identified with DAVID http://
david.abcc.ncifcrf.gov/.
Conclusion: Experimental results with gene expression data demonstrate that the proposed
methods can be utilized to identify important genes and pathways that are related to cancer and
build a parsimonious model for future patient predictions.
Background
Gene selection and cancer prediction with microarray
data have been studied extensively in recent years. Most
earlier studies concentrated on identifying a small
number of discriminatory genes with different statistical
and machine learning methods [1-3]. Many statistical
learning techniques such as support vector machines [4],
the relevance vector machines (RVM) [5,6], LASSO [7-9],
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and sparse logistic regression [10-12] have been applied
to this problem. There are two common goals for such
algorithms: The first is to distinguish cancer and non-can-
cer patients with the highest possible accuracy. The second
is to identify a small subset of genes that are highly differ-
entiated in different classes and to associate gene expres-
sion patterns with disease status. The genes identified with
the second aim may improve our understanding of the
underlying causes of the cancer. In gene selection, when
genes share the same biological pathway, the correlation
between them can be high [13], and those genes form a
group. The ideal gene selection methods eliminate the
trivial genes and automatically include the whole group
genes into the model once one gene among them is
selected. Most importantly, almost all of the current meth-
ods are biased towards selecting those genes that display
the most pronounced expression differences. Such meth-
ods select genes using purely statistical criteria (either rank
score or classification accuracy) and this selection is
thought to reflect their relative importance. Quite often, a
certain number of genes with the smallest p-values or
highest prediction accuracy are finally selected, while
most biologists recognize that the magnitude of differen-
tial expression does not necessarily indicate biological sig-
nificance. From the biological prospective, even a very
small change in the expression of a particular gene may
have dramatic physiological consequences if the protein
encoded by this gene plays a catalytic role in a specific cell
function [14]. Many other downstream genes may
amplify the signal produced by this truly interesting gene,
thereby increasing their chance of being selected by cur-
rent gene selection methods. For a regulatory gene, how-
ever, the chance of being selected by such methods may
diminish as one keeps hunting for downstream genes that
tend to show much bigger changes in their expression. As
a result, the initial list of candidate genes may be enriched
with many effector genes that do little to elucidate more
fundamental mechanisms of biological processes. There-
fore we have to deal with two important problems in gene
selection: (1) how to take into account the gene-gene cor-
relations and (2) how to hunt the upstream regulatory
genes. The characteristic of the regulatory genes is that
their gene expression changes may be low, but they are
highly correlated with the downstream highly expressed
genes. Although there is ongoing research to incorporate
prior biological knowledge, such as partially known path-
ways in gene selection [15], to the best of our knowledge,
there is no efficient method to hunt the upstream regula-
tory genes in gene selection and pathway discovery. There
is, therefore, a pressing need for new algorithms to be
developed.
In this paper, we propose a substantial improvement to
the sparse logistic regression (SparseLOGREG) approach
[12]. The SparseLOGREG algorithm employs a Lp norm
regularization [16], which is equivalent to super Laplace
prior over the model parameters. Both the generalization
ability of the model and the sparsity achieved are critically
dependent on the value of a regularized parameter, which
has to be carefully tuned to the best performance. This
best parameter can only be found through cross-valida-
tion and computationally intensive search. In this paper,
the regularization parameter, however, will be integrated
out analytically using a new prior that is similar to the
uninformative Jeffery's prior [11]. The resulting algorithm
(BLpLog) has the comparable performance with the orig-
inal algorithm but is much faster, as there is no longer a
need for parameter optimization. The goal of the current
study is to develop a computationally affordable and well-
behaved estimating approach, which can effectively iden-
tify cancer related genes and pathways. We propose an
integrated method that first identifies a small subset of
cancer related genes utilizing the Lp regularized Bayesian
logistic regression (BLpLog), and then define a novel sim-
ilarity measure to identify the regularized genes that are
highly correlated with each gene in the subset. Finally, we
annotate the regularized genes and identify the cancer
related pathways using DAVID.
Results and discussion
In this section, we evaluate the performance of proposed
Lp penalized Bayesian logistic regression (BLpLog) meth-
ods and the integrated algorithm using several microarry
data. We compare proposed method with SparseLOGREG
[12] and BLogReg [11].
SparseLOGREG includes a regularization parameter, con-
trolling the complexity of the model and the sparsity of
the model parameters, which must be chosen by the user
or alternatively optimized in an additional model selec-
tion stage. Therefore, the value of this parameter is found
via a (computationally expensive) maximization of the
cross-validation estimate of the area under the ROC curve
(AUC). However, we cannot use the same cross-validation
estimate for both model selection and performance eval-
uation as this would introduce a strong selection bias in
favor of the existing sparse SparseLOGREG model. A
nested cross-validation procedure is therefore used
instead. 10-fold cross validation is used for performance
evaluation in the 'outer loop' of the procedure, in each
iteration of which model selection is performed individu-
ally for each classifier based on a separate leave-one-out
cross-validation procedure using the training data only.
Because of the small sample size and high dimensional
genes, leave-one-out cross validation in the 'inner loop'
likely provide a reliable performance measure for model
selection. Even though this nested cross-validation is
computationally expensive, it provides an almost unbi-
ased assessment of generalization performance as well as
a sensible automatic method of setting the value of theBMC Bioinformatics 2008, 9:412 http://www.biomedcentral.com/1471-2105/9/412
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regularization parameter. We do not need model selection
with both BLpLog and BLogReg, only 10-fold cross valida-
tion is used for performance evaluation. Finally, we find
the highly correlated upstream genes with proposed corre-
lation measure and identify the related pathways using
DAVID.
Breast Cancer Data Set [17]
98 primary breast cancers (34 from patients who devel-
oped distant metastases within 5 years, 44 from patients
who continue to be disease-free after a period of at least 5
years, 18 from patients with BRCA1 germline mutations
and 2 from BRCA2 carriers) have been selected from
patients who were lymph node negative and under 55
years of age at diagnosis. There is a total of 24188 genes.
This data set contained some missing values. Gene expres-
sion levels lacking for all patients are left out. The rest of
the missing values are estimated based on the correlations
between gene expressions.
We apply the proposed integrated algorithm to the data.
BLpLog identifies 11 genes with the 10-cross-validation
AUC = 0.976. These 11 genes are highly differentiated in
patients with and without metastases. SparseLOGREG
selects 10 highly differentiated genes with predicted AUC
= 0.981, and BLogReg identifies 14 genes with the pre-
dicted AUC = 0.953. Both SparseLOGREG and BLpLog
outperform BLogReg with higher AUC value and less
genes. but that the difference in performance between the
SparseLOGREG and BLpReg algorithms is minimal. The
BLpLog algorithm is marginally more computational
expensive than the BLogReg with multiple initializations.
It takes 5 minutes compare 1.7 minutes with BLogReg
algorithm. The SparseLOGREG algorithm is very much
more expensive, owing to the need for a model selection
stage to choose a good value for the regularization param-
eter. It takes roughly 4 hours on the same PC. Given the
minimal difference in performance and substantial differ-
ence in computational expense there is little reason to pre-
fer the SparseLOGREG over the BLpLog algorithm. We
find the correlated genes for each of the 11 selected genes
using the criteria |R| > 0.9 and identify pathways that asso-
ciated with those genes with DAVID. The 11 genes with
BLpLog are listed in Table 1. Each pathway is identified in
such a way that the statistical significance of the pathway
is the highest (p value is the smallest) in DAVID. The '+'
and '-' signs in column 2 of Table 1 indicate that the
selected gene is either over-expressed or down-expressed
for patients with metastases. The total number of highly
correlated genes with each selected gene is given in col-
umn 4. The highly correlated genes on a KEGG pathway
are shown in Table 2. Six pathways associated with 7
selected genes are identified. The correlated genes of the 4
other selected do not have a KEGG pathway associated
with them. The plots of T cell receiptor signaling and
MAPK signaling pathway are shown in Figure 1 – Figure 2.
The over-expressed and and down-expressed genes on the
pathway are shown in red and blue respectively. Each of
these six pathways plays an important role in breast cancer
survivals. For instance, JAK/STAT signaling pathway is the
principal signaling mechanism for a wide array of
cytokines and growth factors. JAK activation stimulates
cell proliferation, differentiation, cell migration and
apoptosis. These cellular events are critical to hematopoi-
esis, immune development, mammary gland develop-
ment and lactation, adipogenesis, sexually dimorphic
growth and other processes. Predictably, mutations that
reduce JAK/STAT pathway activity affect these processes.
Conversely, mutations that constitutively activate or fail
to regulate JAK signaling properly cause inflammatory dis-
ease, erythrocytosis, gigantism and different cancers.
Moreover, LEUKOCYTE TRANSENDOTHELIAL MIGRA-
TION provides relevant information about how cells
interact with the endothelium and transmigrate. Transen-
dothelial migration of cancer cells from the vasculature
into tissue stroma is a final step in the metastatic cascade,
prior to formation of secondary tumors. Patients who
developed distant metastases in less than 5 years and
those who had no distant metastases have 8 genes differ-
entially expressed. The proposed integrated algorithm
Table 1: BLpLog selected genes and the number of correlated
Gene ID Gene Name Gene Description # of Corr. Genes.
Contig27800_RC SFTPD (+) surfactant, pulmonary associated protein D 213
NM_000909 STXBP1 (-) syntaxin binding protein 1 411
NM_003147 (-) ESTs 229
Contig23399_RC (-) ESTs 227
Contig38438_RC (-) ESTs 327
NM_003882 (-) ESTs 110
AF221520 LOC51241 (+) hypothetical protein 274
AL080059 TCP1 (+) t-complex 1 169
U79298 ACTR2 (-) ARP2 homolog 46
NM_001197 FLJ10375 (-) hypothetical protein FLJ10375 10
NM_000599 ZNF83 (+) hypothetical protein FLJ11015 30BMC Bioinformatics 2008, 9:412 http://www.biomedcentral.com/1471-2105/9/412
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Table 2: Highly correlated genes and KEGG pathway
Genes Gene Description Pathway
STXBP1 NM_000909
CNTFR ciliary neurotrophic factor receptor JAK-STAT SIGNALING PATHWAY
PRL prolactin
SOCS3 suppressor of cytokine signaling 3
EPOR erythropoietin receptor
JAK2 janus kinase 2
CBL cas-br-m (murine) ecotropic retroviral transforming sequence
IL5RA interleukin 5 receptor, alpha
ESTs NM_003147
SEMA3E sema domain, immunoglobulin domain, short basic domain, 
(semaphorin) 3e
AXON GUIDANCE
RASA1 ras p21 protein activator (gtpase activating protein) 1
SLIT3 slit homolog 3 (drosophila)
SRGAP3 slit-robo rho gtpase activating protein 3
EFNA5 ephrin-a5
ESTs Contig38438
CLDN14 claudin 14 LEUKOCYTE TRANSENDOTHELIAL MIGRATION
MAPK13 mitogen-activated protein kinase 13
CLDN4 claudin 4
RAP1B member of ras oncogene family
PTK2B protein tyrosine kinase 2 beta
CDC42 cell division cycle 42
MYL6 myosin, light polypeptide 6, smooth muscle and non-muscle
VCL vinculin
ESTs + ACTR2 NM_003882 + U79298
STMN1 stathmin 1/oncoprotein 18 MAPK SIGNALING PATHWAY
MAPK13 mitogen-activated protein kinase 13
MAP2K3 mitogen-activated protein kinase kinase 3
NFATC4 nuclear factor of activated t-cells, cytoplasmic, calcineurin-dependent 4
CACNA1H calcium channel, voltage-dependent, alpha 1 h subunit
ARRB2 arrestin, beta 2
FGFR3 fibroblast growth factor receptor 3
ELK4 elk4, ets-domain protein
IKBKE inhibitor of kappa light polypeptide gene enhancer in b-cells, kinase 
epsilon
LOC51241 AF221520
VAV2 vav 2 oncogene T CELL RECEPTOR SIGNALING PATHWAY
IL2 interleukin 2
CHUK conserved helix-loop-helix ubiquitous kinase
MALT1 mucosa associated lymphoid tissue lymphoma translocation gene 1
CBL cas-br-m (murine) ecotropic retroviral transforming sequence
TCP1 AL080059
COX10 cox10 homolog, cytochrome c oxidase assembly protein OXIDATIVE PHOSPHORYLATION
ATP6V0A2 atpase, h+ transporting, lysosomal v0 subunit a2
COX4I1 cytochrome c oxidase subunit iv isoform 1
COX6B1 cytochrome c oxidase subunit vib polypeptide 1 (ubiquitous)BMC Bioinformatics 2008, 9:412 http://www.biomedcentral.com/1471-2105/9/412
Page 5 of 19
(page number not for citation purposes)
provides information not only about the set of genes
involved on these pathways, but also about how genes
interact and regulate each other. In this manuscript, we
will only discuss both T CELL RECEPTOR SIGNALING
PATHWAY and MAPK SIGNALING PATHWAY in more
detail. Other pathways can be analyzed in a similar fash-
ion.
T Cell Receptor (TCR) Signaling (Figure 1) induces activa-
tion of multiple tyrosine kinases, resulting in the phos-
phorylation of numerous intracellular substrates. One of
the first steps in the generation of the immune response is
the recognition by T lymphocytes of peptide fragments
(antigens) derived from foreign pathogens that are pre-
sented on the surface of antigen presenting cells (APC).
This event is mediated by the T cell receptor (TCR), which
transduces these extracellular signals by initiating a wide
array of intracellular signaling pathways. This signaling
pathway is one of the identified targets for breast cancer
drug development. We identified 5 genes on the pathway:
CBL, VAV, MALT1, CHUK (IKKα), and IL-2. VAV2,
MALT1, and CHUK(IKKα) are also on the B-cell receiptor
signal pathway. Among them, only gene VAV2 is down-
expressed in patients with distant metastases in less than
5 years. The other 4 genes are up-expressed. VAV2 is an
oncogene and plays a critical role in hematopoietic signal
transduction. The down-expressed Vav2 has been impli-
cated in breast cancer metastasis and may prove to be very
T Cell Receiptor Signaling Pathway Figure 1
T Cell Receiptor Signaling Pathway. T-cell receipt signaling pathway and the associated genes identified with the inte-
grated algorithm. The over-expressed and down-expressed genes on the pathway are shown in red and blue respectively.BMC Bioinformatics 2008, 9:412 http://www.biomedcentral.com/1471-2105/9/412
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important in the aberrant activation of Rho GTPases dur-
ing the metastatic cascade. The other 4 over-expressed
genes are also very important for breast and other cancers
and were well studied in the literature. For example, the
CBL oncogene was first identified as part of a transform-
ing retrovirus which induces mouse pre-B and pro-B cell
lymphomas. As an adaptor protein for receptor protein-
tyrosine kinases, it positively regulates receptor protein-
tyrosine kinase ubiquitination in a manner dependent
upon its variant SH2 and RING finger domains. Ubiquiti-
nation of receptor protein-tyrosine kinases terminates sig-
naling by marking active receptors for degradation.
MALT1, CHUK, and IL-2 are also important oncogene
identified. These 3 genes have the causal relations as
shown in Figure 1. MALT1 is defined as the mucosa asso-
ciated lymphoid tissue lymphoma translocation gene 1.
The over-expressed MALT2 in patients with distant metas-
tasis causes the over-expressed CHUK, and then the over-
expressed IL-2. Therefore, MALT1 is essential for T cell
activation, proliferation, and IL-2 production. If MALT1 is
not present, both CHUK and IL-2 will shut-off.
The Mitogen-Activated Protein Kinase (MAPK) signaling
pathway (Figure 2) transduces a large variety of external
signals, leading to a wide range of cellular responses,
including growth, differentiation, inflammation and
apoptosis. The MAPK signaling pathway has been linked
to being responsible for the malignant phenotype, includ-
ing increased proliferation, defects in apoptosis, invasive-
ness and ability to induce neovascularization.
MAPK Signaling Pathway Figure 2
MAPK Signaling Pathway. MAPK signaling pathway and the associated genes. The over-expressed and down-expressed 
genes on the pathway are shown in red and blue respectively.BMC Bioinformatics 2008, 9:412 http://www.biomedcentral.com/1471-2105/9/412
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Consequently, different therapies towards inhibiting the
pathway are under development. Nine genes were identi-
fied on the pathway. Patients with metastases in less than
5 years are over-expressed in 8 genes and down-expressed
in one gene (Table 2 and Figure 2).
There are several causal relations among them. For
instance, EGFR belong to the family of epidermal growth
factor receptors and has been proven to play major roles
in different histological types of breast cancer. The over-
expressed EGFR in patients with metastases may be
responsible for the up-expressed STMN1 and the down-
expressed ELK4 (Sap1a). ELK4 is a downstream gene on
the MAPK pathway. Moreover, the the over-expressed
MAP2K3 (MKK3) causes the over-expressed
MAPK12(P38), and then causes the down-expressed ELK4
(Sap1a). The systematic review of the interactions among
the correlated genes on a specific pathway provides us
more information about how various genes interact with
each other and which gene plays a catalytic role and is
more important. EGFR3 is certainly a more important
upstream gene and mutations that lead to EGFR over-
expression (or overactivity) have been associated with a
number of cancers. The over-expressed EGFR in patients
with metastases has led to the development of anticancer
therapeutics directed against EGFR.
Hepatocellular carcinoma data set [18]
mRNA expression profiles in tissue specimens from 60
hepatocellular carcinoma tissues of which 20 suffer from
early intrahepatic recurrence and 40 do not. The number
of gene expression levels is 7129. Since hepatocellular car-
cinoma has a poor prognosis because of the high intrahe-
patic recurrence rate, the original goal is to predict early
intrahepatic recurrence or non-recurrence. With the pro-
posed integrated algorithm, we can identify not only the
highly differentiated genes but also the related pathways.
BLpLog identifies 8 highly differentiated genes with the
test AUC = 0.93 with the computational time of 3.2 min-
utes. BLogReg selects 13 genes with the predicted AUC =
0.90 and computational time of 1.6 minutes. SparseLO-
GREG identifies 10 genes with the predicted AUC = 0.936
and computational time of 127 minutes (2 hours). The
selected genes with different methods are not completely
the same but highly correlated. Again with the minimal
difference in performance and big differences in computa-
tional time between BLpLog and SparseLOGREG, obvi-
ously BLpLog is preferred. The highly correlated genes and
corresponding pathways are selected with the integrated
algorithm. Table 3 and Table 4 are the computational
results. Seven pathways was identified from the data. The
plots of Antigen Processing and Presentation and Axon
Guidance pathways are shown in Figure 3 – Figure 4. All
eight pathways identified are important in hepatocellular
carcinoma and other cancers. For example, PURINE
METABOLISM pathway is one of the metabolism path-
ways involved in nucleotide synthesis and degradation,
amino acid catabolism, non-essential amino acid synthe-
sis and the urea cycle. Understanding the mechanism
involved in metabolic regulation has important implica-
tions in both biotechnology and medicine. It is estimated
that at least a third of all serious health problems are
caused by metabolic disorders. Analyzing differentiated
expressed genes on the pathway may provide some insight
on the early intrahepatic recurrence of hepatocellular car-
cinoma after curative resection. Other pathways such as
CYTOKINE-CYTOKINE RECEPTOR INTERACTION,
NEUROACTIVE LIGAND-RECEPTOR INTERACTION,
MAPK SIGNALING PATHWAY, and GAP JUNCTION are
all hepatocellular carcinoma related. We will discuss the
two pathways ANTIGEN PROCESSING AND PRESENTA-
TION and AXON GUIDANCE in more details.
ANTIGEN PROCESSING AND PRESENTATION are proc-
esses that occur within a cell that result in fragmentation
(proteolysis) of proteins, association of the fragments
with MHC molecules, and expression of the peptide-MHC
molecules at the cell surface where they can be recognized
by the T cell receptor on a T cell. However, the path lead-
ing to the association of protein fragments with MHC
molecules differs for class I and class II MHC. MHC class
I molecules present degradation products derived from
intracellular (endogenous) proteins in the cytosol. MHC
class II molecules present fragments derived from extracel-
lular (exogenous) proteins that are located in an intracel-
Table 3: BLpLog selected genes and the number of correlated
A3y ID Gene Description # of Corr. Genes
D26600_at (+) Human mRNA for proteasome subunit HsN3 133
M16973_at (-) Human complement protein C8 beta subunit mRNA 124
M63573_at (+) Human secreted cyclophilin-like protein (SCYLP) mRNA 103
U79294_at(-) Human clone 23748 mRNA, complete cds 102
U94586_at(+) ubiquinone oxidoreductase MLRQ subunit mRNA 122
X00274_at(-) Human gene for HLA-DR alpha heavy chain a class II antigen (immune response gene) of the MHC 92
X59798_at (+) Human PRAD1 mRNA for cyclin 107
X69141_at (+) H. sapiens mRNA for squalene synthase 99BMC Bioinformatics 2008, 9:412 http://www.biomedcentral.com/1471-2105/9/412
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Table 4: KEGG pathway and the highly correlated genes
Genes Gene Description Pathway
D26600_at and X59798_at
X06562_at growth hormone receptor CYTOKINE-CYTOKINE RECEPTOR
X95095_at platelet-derived growth factor receptor, alpha polypeptide
M12783_at platelet-derived growth factor beta polypeptide (simian sarcoma 
viral (v-sis) oncogene homolog)
M20137_at interleukin 3 (colony-stimulating factor, multiple)
L36033_at chemokine (c-x-c motif) ligand 12 (stromal cell-derived factor 1)
V00532_rna1_f_at interferon, alpha 17
U11877_at interleukin 8 receptor, beta
V00542_f_at interferon, alpha 14
D49410_at interleukin 3 receptor, alpha (low affinity)
X04688_at interleukin 5 (colony-stimulating factor, eosinophil)
X02958_at interferon, alpha 6
X00695_s_at interleukin 2
U02687_at fms-related tyrosine kinase 3
M83554_at tumor necrosis factor receptor superfamily, member 8
D43767_at chemokine (c-c motif) ligand 17
X02958_at interferon, alpha 1
U83326_s_at chemokine (c-c motif) receptor 5
X02958_at interferon, alpha 5
M16973_at
M86868_at gamma-aminobutyric acid (gaba) receptor, rho 2 NEUROACTIVE LIGAND RECEPTOR INTERACTION
U49395_at purinergic receptor p2x, ligand-gated ion channel, 5
U68133_at cannabinoid receptor 1 (brain)
K01911_at neuropeptide y
M31210_at endothelial di3erentiation, sphingolipid g-protein-coupled 
receptor, 1
D85376_at thyrotropin-releasing hormone receptor
M18185_at gastric inhibitory polypeptide
L27080_at melanocortin 5 receptor
X82068_at glutamate receptor, ionotrophic, ampa 3
M63573_at
U61538_at calcium binding protein p22 AXON GUIDANCE
M14949_at related ras viral (r-ras) oncogene homolog
L36033_at chemokine (c-x-c motif) ligand 12 (stromal cell-derived factor 1)
X17576_at nck adaptor protein 1
M17219_at guanine nucleotide binding protein (g protein), alpha inhibiting 
activity polypeptide 1
L41939_at eph receptor b2
X76132_at deleted in colorectal carcinoma
U79294
M92432_at guanylate cyclase 2d, membrane (retina-specific) PURINE METABOLISM
U40370_at phosphodiesterase 1a, calmodulin-dependent
Y00971_at phosphoribosyl pyrophosphate synthetase 1
X59618_at ribonucleotide reductase m2 polypeptide
Z46632_at phosphodiesterase 4c, camp-specific
U94586_at
HT3620_s_at fibroblast growth factor receptor 2 MAPK SIGNALING PATHWAY
M76559_at calcium channel, voltage-dependent, alpha 2/delta subunit 1
M38449_s_at transforming growth factor, beta 1BMC Bioinformatics 2008, 9:412 http://www.biomedcentral.com/1471-2105/9/412
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lular compartment. Both MHC class I and class II
pathways play an important role in anti-tumor immune
responses. Patients with early intrahepatic recurrence of
hepatocellular carcinoma (HCC) have the down-
expressed expression both on MHC I and II pathways. It is
generally acknowledged that tumors usually escape from
host immune surveillance by dysfunction or defect of
MHC I and MHC II presentation pathways with the down-
expressed genes. Therefore, the down-expressed genes on
the pathway may be one of the critical reasons for early
intrahepatic recurrence. The causal relations among genes
can also be identified in Figure 3. The down-expressed
MHCI gene may cause the down-expressed β2m and the
down-expressed MHCII and/or LI gene may cause the
down-expressed SLIP and the down-expressed SLIP may
cause the down-expressed CLIP. These causal relations
may provide some implications on developing medicines
against hepatocellular carcinoma. AXON GUIDANCE
(also called axon pathfinding) is a subfield of neural
development concerning the process by which neurons
send out axons to reach the correct targets. Many axon
guidance molecules may regulate cell migration and
apoptosis in normal and tumorigenic tissues. Recent stud-
ies have shown that they are widely expressed outside the
nervous system and that they may play important roles in
HCC. Genes and their interactions are shown in Figure 4.
For example, mutations in the ras oncogenes have been
linked to many different cancers. Ras gene is over-
expressed for HCC patients with early intrahepatic recur-
rence. The causal relations and gene-gene interactions are
also shown in Figure 4. For instance, the down-expressed
EpbB gene in patients with intrahepatic recurrence may
cause the over-expressed ras gene through MAPK signaling
pathway. The over-expressed DCC gene in patients with
intrahepatic recurrence may cause the down-expressed
Nck1 and over-expressed CALN, and so on. These gene-
gene interactions may have prognostic implications for
HCC.
High-grade glioma data set [19]
50 high-grade glioma samples were carefully selected, 28
glioblastomas and 22 anaplastic oligodendrogliomas, all
were primary tumors sampled before therapy. The classic
subset of tumors were cases diagnosed similarly by all
examining pathologists, and each case resembled typical
depictions in standard textbooks. A total of 21 classic
tumors was selected, and the remaining 29 samples were
considered nonclassic tumors, lesions for which diagnosis
might be controversial. Affymetrix arrays are used to deter-
mine the expression of over 12000 genes. The original
goal is to separate the glioblastomas from the anaplastic
oligodendrogliomas, which allows appropriate therapeu-
tic decisions and prognostic estimation. The number of
gene expression levels is 12625. Our goal is to identify
genes and corresponding pathways associated with malig-
nant gliomas.
U66464_at mitogen-activated protein kinase kinase kinase kinase 1
U71087_at mitogen-activated protein kinase kinase 5
U13021_s_at caspase 2, apoptosis-related cysteine peptidase 
(neural precursor cell expressed, developmentally down-regulated 
2)
D12625_at neurofibromin 1
S78187_at cell division cycle 25b
X00274_at
M33600_f_at major histocompatibility complex, class ii, dr beta 1 ANTIGEN PROCESSING AND PRESENTATION
X00274_at major histocompatibility complex, class ii, dr alpha
X03100_cds2 major histocompatibility complex, class ii, dp alpha 1
M13560_s_at cd74 antigen 
(invariant polypeptide of major histocompatibility complex, class ii 
antigen-associated)
D45248_at proteasome (prosome, macropain) activator subunit 2
J00105_s_at beta-2-microglobulin
M17236_s_at major histocompatibility complex, class ii, dq alpha 1
HG658-
HT658_f_at
major histocompatibility complex, class i, b
X69141_at
Y07512_at protein kinase, cgmp-dependent, type i GAP JUNCTION
M18255_cds2_s_at protein kinase c, beta 1
Z11695_at mitogen-activated protein kinase 1
X80763_s_at 5-hydroxytryptamine (serotonin) receptor 2c
Table 4: KEGG pathway and the highly correlated genes (Continued)BMC Bioinformatics 2008, 9:412 http://www.biomedcentral.com/1471-2105/9/412
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BLpLog has identified 14 genes that are highly differenti-
ated expressed in glioblastomas and anaplastic oligoden-
drogliomas (predicted AUC = 0.98). Eight pathways and
associated correlated genes are identified with the inte-
grated algorithm. The computational results are given in
Table 5 and 6. The plots of FOCAL ADHESION and
RIBOSOME pathways are shown in Figure 5 – Figure 6.
The eight identified pathways are important in malignant
gliomas and other diseases. For instance, COMPLEMENT
AND COAGULATION CASCADES are composed of ser-
ine proteases that are activated through partial cleavage by
an upstream enzyme. The elements of these cascades
share several common structural characteristics, including
a highly conserved catalytic site composed of Ser, His and
Asp. The common principle underlying the organization
of these systems is that proteases exist as inactive
zymogens and are subsequently activated by upstream,
active proteases. The initial activation might occur as a
result of contact with a non-enzymatic ligand or cleavage
by another protease. Understanding the interplay
between complement and coagulation has fundamental
clinical implications in the context of cancers with an
inflammatory pathogenesis. Migration and invasion are
important prerequisites for the infiltrative and destructive
growth patterns of malignant gliomas. The glioma cell
invasiveness depends on proteases of the coagulation and
complement cascades. Another pathway, GLUTATHIONE
METABOLISM, works through the operation of a group of
enzymes called glutathione S-transferases (GST). Glutath-
ione (GSH) plays a critical role in cellular mechanisms
that result in cell death. The high glutathione levels may
cause resistance to chemotherapy drugs. One interesting
Antigen Processing and Presentation Figure 3
Antigen Processing and Presentation. Antigen processing and presentation pathway and the associated genes. The over-
expressed and down-expressed genes on the pathway are shown in red and blue respectively.BMC Bioinformatics 2008, 9:412 http://www.biomedcentral.com/1471-2105/9/412
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study by researchers in Texas showed that your chances of
surviving a type of brain cancer, called primary malignant
glioma, could depend on the type of glutathione-s-trans-
ferase (GST) gene you were born with. Therefore, it is pos-
sible to target glutathione metabolism in the prevention
and treatment of malignant gliomas. Here we discuss the
FOCAL ADHESION and RIBOSOME pathways in more
details.
FOCAL ADHESIONS are large, dynamic protein com-
plexes through which the cytoskeleton of a cell connects
to the extracellular matrix, or ECM. They can be consid-
ered as sub-cellular macromolecules that mediate the reg-
ulatory effects (e.g. cell anchorage) of extracellular matrix
(ECM) adhesion on cell behavior. Focal adhesions kinase
(FAK) contributes to glioma growth and invasion. FAK
integrates signals from activated growth factor receptors
and integrins to regulate cell motility, invasion, prolifera-
tion, apoptosis, and angiogenesis. It, therefore, promotes
tumor growth, and a role for FAK in glioma pathogenesis
is suggested by its expression and localization. FAK genes
are over-expressed on the pathway for glioblastoma
patients as shown in Figure 5. These over-expressed genes
may have many potential pro-tumorigenic functions and
produce chemotherapy resistance in the glioblastoma
patients. The causal relations and gene-gene interactions
are also shown in Figure 5. The over-expressed ECM gene
is a causal gene that causes several other genes to be over-
expressed. If ECM is not present, the entire pathway is
shut off. Conversely, the expression changes of down-
stream genes such as MLC and PAK may not affect the
pathway as much.
Axon Guidance Figure 4
Axon Guidance. Axon guidance pathway and the associated genes. The over-expressed and down-expressed genes on the 
pathway are shown in red and blue respectively.BMC Bioinformatics 2008, 9:412 http://www.biomedcentral.com/1471-2105/9/412
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Ribosome biology is huge and accounts for up to 50% of
transcriptional activity of cells. The RIBOSOME pathway
is composed of genes that encode various proteins of the
ribosomal subunits. These proteins need to interact phys-
ically with each other to form a large protein complex, the
ribosome, and are thereby closely related functionally.
Ribosome biogenesis and translation are regulated at mul-
tiple levels and are associated with accurate cell growth
and proliferation. Several tumor suppressors and proto-
oncogenes have been found either to affect the formation
of the mature ribosome or to regulate the activity of pro-
teins known as translation factors. Disruption in one or
more of the steps that control protein biosynthesis has
been associated with alterations in the cell cycle and regu-
lation of cell growth. Therefore, certain tumor suppressors
and proto-oncogenes might regulate malignant progres-
sion by altering the protein synthesis machinery. The pro-
tein genes on RIBOSOME pathway (Figure 6) are down-
expressed in glioblastoma patients. These down-expressed
genes may provide some insight on how to develop new
drugs and cancer therapies to target the RIBOSOME path-
way involved in malignant gliomas.
Conclusion
We have developed a Bayesian Lp  Logistic regression
(BLpLog) method, defined a novel correlation measure,
and proposed an integrated algorithm for gene selection
and pathway identification. We have demonstrated that
the simple Bayesian approach to integrating the regulari-
zation parameter out analytically performed well on pre-
diction. The integrated algorithm can identify cancer
associated genes and KEGG pathways efficiently with the
test data sets. The correlation measure we defined can be
used to hunt those upstream regularized genes with low
expression levels, but are strongly correlated with the
downstream highly differentiated genes identified with
BLpLog. Almost all of the pathways found in this manu-
script cannot be identified with the traditional correlation
coefficient. The identified pathways can provide informa-
tion on gene-gene interactions and causal relations for
genes on the pathway. The knowledge of gene-gene inter-
action, gene regulation, and biological pathways can be
applied to understanding the mechanisms of how path-
way regulations have changed in different subtypes of can-
cer patients.
Mining high throughput data from different aspects can
help us understand the cancer biology better. Our method
provided much more information than we presented. For
instance, we found hundreds of correlated genes for each
downstream gene identified with BLpLog. Only a small
proportion of the correlated genes is on the known KEGG
pathways. We did not explore the functions and causal
relations of the rest of the genes. Moreover, although there
may be multiple pathways for each gene, we only reported
the top pathway with the highest count of genes. We will
infer the gene regulatory networks with the rest of the cor-
related genes and explore multiple pathways in the near
future. Finally, gene set enrichment analysis [20] is a pop-
ular tool for evaluating microarray data at the level of gene
sets. It, first, utilize a statistical test to identify highly dif-
ferentiated upstream genes in two classes, and then define
gene sets based on prior biological knowledge. There are
two drawbacks with this method: (1) it is solely based on
the partially known biological knowledge and (2) it can-
not guarantee the upstream regularized genes to be
selected in the set. It is, therefore, of great interests to
incorporate the proposed correlation measure R into gene
enrichment analysis, so that we can make sure the
upstream regularized genes in the studied gene sets. This
is the work of our future research.
Methods
Lp Regularized Sparse Logistic Regression
A general binary classification problem may be simply
described as follows. Given n samples, D = {(x1, y1), ...,
Table 5: BLpLog selected genes and the number of correlated
AFFY ID Gene Description # of corr Genes
yj12d03.s1 (+) Soares placenta Nb2HP Homo sapiens cDNA clone IMAGE 148517 3 189
245_at(-) HUMLNHR Human lymph node homing receptor mRNA, complete cds 149
32140_at (-) H. sapiens mRNA for mosaic protein LR11 140
33117_r_at (-) oq25a04.s1 Homo sapiens cDNA, 3 end 139
34279_at (+) Homo sapiens mRNA 154
34645_at (-) Human Hums3 mRNA for 40S ribosomal protein s3 76
35628_at (-) Homo sapiens lamin B receptor homolog TM7SF2 mRNA, complete cds 191
36452_at (+) Homo sapiens mRNA for KIAA1029 protein, complete cds 165
37591_at (-) Human uncoupling protein homolog (UCPH) mRNA, complete cds 228
37915_at (+) cDNA DKFZp434H071 (from clone DKFZp434H071) 290
38079_at (+) cDNA DKFZp586B0918 (from clone DKFZp586B0918) 213
40419_at (-) H. sapiens epb72 gene exon 1 204
41213_at (+) H. sapiens mRNA for proliferation associated gene (pag) 158
675_at (-) HUM927A Human interferon-inducible protein 9–27 mRNA, complete cds 210BMC Bioinformatics 2008, 9:412 http://www.biomedcentral.com/1471-2105/9/412
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Table 6: KEGG pathway and the highly correlated genes
Genes Gene Description Pathway
yj12d03.s1 and 35628)_at
33520_at coagulation factor vii (serum prothrombin conversion accelerator) COMPLEMENT AND COAGULATION CASCADES
31591_s_at complement factor h
37550_at coagulation factor viii, procoagulant component (hemophilia a)
41701_at complement component 6
37175_at serpin peptidase inhibitor, clade c (antithrombin), member 1
245_at and 36452_at
2023_g_at v-akt murine thymoma viral oncogene homolog 2 FOCAL ADHESION
40438_at protein phosphatase 1, regulatory (inhibitor) subunit 12a
1560_g_at p21 (cdkn1a)-activated kinase 2
40162_s_at cartilage oligomeric matrix protein
33994_g_a
t
myosin, light polypeptide 6, alkali, smooth muscle and non-muscle
33627_at phosphoinositide-3-kinase, catalytic, delta polypeptide
659_g_at thrombospondin 2
32029_at 3-phosphoinositide dependent protein kinase-1
39765_at talin 2
41350_at collagen, type vi, alpha 1
954_s_at protein phosphatase 1, catalytic subunit, alpha isoform
38812_at laminin, beta 2 (laminin s)
37909_at laminin, alpha 3
34724_at glucocorticoid receptor dna binding factor 1
1557_at p21/cdc42/rac1-activated kinase 1
32140_at
33134_at adenylate cyclase 3 GAP JUNCTION
429_f_at tubulin, beta 2b
429_f_at tubulin, beta 2a
1000_at mitogen-activated protein kinase 3
429_f_at tubulin, beta 4
33117_r_at and 34645_at
32440_at ribosomal protein l17 RIBOSOME
32337_at ribosomal protein l21
31907_at ribosomal protein l14
36333_at ribosomal protein l7
31952_at ribosomal protein l6
32437_at ribosomal protein s5
35119_at similar to ribosomal protein l13a
31957_r_at ribosomal protein, large, p1
34645_at ribosomal protein s3
31538_at ribosomal protein, large, p0
31722_at ribosomal protein l3
31545_at ribosomal protein s18
32466_at ribosomal protein l41
34593_g_a
t
ribosomal protein s17
35119_at ribosomal protein l13a
32394_s_at ribosomal protein l23
41178_at ribosomal protein l11
33117_r_at ribosomal protein s12
36786_at ribosomal protein l10a
37591_atBMC Bioinformatics 2008, 9:412 http://www.biomedcentral.com/1471-2105/9/412
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37956_at aldehyde dehydrogenase 3 family, member b2 METABOLISM OF XENOBIOTICS BY CYTOCHROME P45
375_at glutathione s-transferase theta 1
37707_i_at alcohol dehydrogenase 5 (class iii), chi polypeptide
33396_at glutathione s-transferase pi
1080_s_at cytochrome p450, family 1, subfamily a, polypeptide 2
37915_at, 38079_at, and 675_at
36294_at serine/threonine kinase 4 MAPK SIGNALING PATHWAY
39647_s_at calcium channel, voltage-dependent, beta 2 subunit
38743_f_at v-raf-1 murine leukemia viral oncogene homolog 1
39932_at dual specificity phosphatase 7
36935_at ras p21 protein activator (gtpase activating protein) 1
1292_at dual specificity phosphatase 2
34006_s_at mitogen-activated protein kinase 8
41432_at ribosomal protein s6 kinase, 90 kda, polypeptide 5
971_s_at transforming growth factor, beta 2
438_at protein kinase, camp-dependent, catalytic, alpha
1239_s_at caspase 2, apoptosis-related cysteine peptidase
38272_at dual specificity phosphatase 14
41226_at dual specificity phosphatase 3
37644_s_at fas (tnf receptor superfamily, member 6)
113_i_at microtubule-associated protein tau
249_at nuclear factor of activated t-cells, cytoplasmic, calcineurin-dependent 
4
1788_s_at dual specificity phosphatase 4
31993_f_at calcium channel, voltage-dependent, beta 2 subunit
38079_at guanine nucleotide binding protein (g protein), gamma 12
1378_g_at nuclear factor of kappa light polypeptide gene enhancer in b-cells 1 
(p105)
34521_at mitogen-activated protein kinase kinase kinase 13
37575_at activating transcription factor 2
1327_s_at mitogen-activated protein kinase kinase kinase 5
40030_at protein kinase, y-linked
36168_at fibroblast growth factor receptor 1
36004_at inhibitor of kappa light polypeptide gene enhancer in b-cells, kinase 
gamma
32304_at protein kinase c, alpha
39822_s_at growth arrest and dna-damage-inducible, beta
31618_at tumor protein p53 (li-fraumeni syndrome)
39672_at protein tyrosine phosphatase, non-receptor type 7
32749_s_at filamin a, alpha (actin binding protein 280)
40419_at
40273_at sphingosine kinase 2 GLYCOSPHINGOLIPID METABOLISM
41568_at arylsulfatase d
38818_at serine palmitoyltransferase, long chain base subunit 1
40214_at udp-glucose ceramide glucosyltransferase
41213_at
556_s_at glutathione s-transferase m4 GLUTATHIONE METABOLISM
556_s_at glutathione s-transferase m1
556_s_at glutathione s-transferase m2 (muscle)
32893_s_at gamma-glutamyltransferase 2
32893_s_at gamma-glutamyltransferase 1
32893_s_at gamma-glutamyltransferase-like 4
Table 6: KEGG pathway and the highly correlated genes (Continued)BMC Bioinformatics 2008, 9:412 http://www.biomedcentral.com/1471-2105/9/412
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(xn, yn)}, where xi is a multidimensional input vector with
dimension d and class label yi ∈ {-1, 1}, find a classifier
f(x) such that for any input x with class label y, f(x) pre-
dicts class y correctly. The logistic regression is:
where w = (w1, ..., wd)T are the parameters which can be
estimated through maximizing the log likelihood or min-
imizing the negative log likelihood.
Different prior assumptions of w in the maximum a-pos-
teriori (MAP) estimation will lead to different regulariza-
tion terms. The sparse parameter estimates can be
achieved with Lp regularization:
E = ED + λLp,( 1 )
where
where λ ≥ 0 is a regularization parameter which must be
tuned and   is the regularization term.
Bayesian Regularization
Choosing the best regularization parameter λ  through
cross-validation is time consuming. Therefore we propose
a Bayesian regularization framework to integrate out the
parameter following the similar methods of [11,21,22].
Minimizing E in equation (1) has the straight forward
Bayesian interpretation. The posterior distribution for w is
given by
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where p(D) = ∫ P(D|w)p(w|λ)dwdλ is a normalization fac-
tor that ensures that the posterior integrates to 1 and is
given by an integral over the parameter space. The distri-
bution of p(D|w) is defined as:
Let's  , and we have  , where m is
the number of non-zero model parameters and obviously
m ≤ d. The prior over model parameter, w, can be defined
as
where   is a normalization
constant for a given λ. Taking the negative logarithm of
the posterior density of equation (2), we have
- log p(w|D) = - log P(D|w) - log p(w|λ) + log p(D).
Therefore,
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- log p(w|D) = ED + λLp + log p(D) - m log λ + log(C(λ)).
(4)
The hyperparameter λ can be integrated out analytically in
the prior distribution p(w|λ).
p(w) = ∫ p(w|λ)p(λ)dλ.
As λ is a scaler, we can assign a new prior such that p(λ) ∝
C(λ)/λ. Substituting equation (3), we have
Using the Gamma integral  , we get
Since  , we have
- log p(w|D) = ED + m log Lp + log p(D) - log Γ(m).
(5)
Let Q = ED + m log Lp, comparing equation (4) with (5),
we have
E = ED + λLp = ED + m log Lp + R = Q + R,
where R = log p(D) - log Γ(m) is a constant not related to
w. Therefore, E and Q are identical up to an additive con-
stant and minimizing E is equivalent to minimizing the
Bayesian regularization error function Q.
The BLpLog Algorithm
To find the optimal value of Q and w, we need to have the
first and/or second order derivative with gradient based
methods. One difficulty with Lp is that it is not differenti-
able at zero and a differentiable approximation of Lp has
to be used. Differentiable approximations typically have a
parameter that controls the trade-off between the smooth-
ness of the approximation and the closeness of the non-
differentiable function which is being approximated. One
approximation which works for p ≤ 1 is
where γ is the smoothing parameter. With this differenti-
able approximation, we get the following modified error
function:
Note that Qγ → Q as γ → 0.
Given a small value γ, the gradient can be calculated as:
where
where vec{·} represents a vector whose i-th element is
given by the expression inside the brackets. The Hessian of
the objective function is:
where
where diag{·} is the diagonal matrix whose i-th diagonal
element is given by the expression inside the brackets. Let
A = diag{g(wTxi)(1 - g(wTxi))},
we have the matrix form of H:
With equation (6) and (8), we may estimate the parame-
ters with Newton's method.
wnew = wold - H-1Ќwlγ (9)
We run the iteration until |wnew - wold| <δ, where δ > 0 is a
small number. In each iteration, m  is not fixed, but
updated as the number of |wi| > β, where β is small posi-
tive number. Other algorithms such as the fixed-Hessian
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or conjugate gradient may also be employed to solve the
above problem. The advantage of Newton's method is
that it converges very fast when near the optimal solution.
This algorithm converges from any initialization and a
local maximum is guaranteed.
There is no regularization parameter tuning in this algo-
rithm, but we have to set several approximation parame-
ters to some reasonable values to allow the algorithm to
be performed well. Theoretically, Lp penalty gives asymp-
totically unbiased estimates of the nonzero parameters
while shrinking the estimates of zero (or small) parame-
ters to zero when p → 0 [16]. Unlike LASSO (with p = 1)
that shrinks every parameter proportionally. Therefore the
lower value of p would lead to more sparse and better
solutions [12]. However when p is very close to zero, dif-
ficulties with convergence arise. Therefore, we set p = 0.1
in this paper. We also set the threshold β = 0.001. The
smoothing parameter γ  appears in the differentiable
approximation to the Lp norm. When γ is too large, the
approximation is not a good one and the solution is
overly smooth and the sparsity property of Lp will be lost.
When γ is very small, the number of iterations required for
convergence increases drastically. We have found empiri-
cally that a choice of γ which does not require very many
iterations, and yet converges to very sharp solutions is
around 0.001–0.0000001 for our data We therefore set γ
= 0.000001 in all experiments.
BLpLog employs a gradient decent method with superlin-
ear convergence. To prevent the optimization from stick-
ing to local optimal, we randomly initialize the
coefficients 20 times and choose the estimated coeffi-
cients with the best AUC value for all of the computa-
tional experiments in this paper. Our experiments,
however, have shown that the computational results are
not sensitive to the parameter initialization and the algo-
rithm converges quickly to the same optimization value
most of the time with different parameter initializations.
Our binary classification algorithm can be extended for
multiclass classification tasks. For a general c-class prob-
lem, we can employ the standard approach where two
class classifiers are trained in order to separate each of the
classes against all others. The decision rules are then cou-
pled by voting, that is, sending the sample to the class
with the largest probability.
Similarity and Integrated Algorithm
In gene selection and pathway discovery, we have to deal
with two important problems: (1) how to take into
account the gene-gene correlations and (2) how to hunt
the upstream regulatory genes. As we discussed in the pre-
vious section, current gene selection methods can only
select the downstream genes with bigger changes in
expression. The characteristic of the regulatory genes is
that their gene expression changes may be low but they
are highly correlated with the downstream highly
expressed genes. We first introduce our own correlation
(similarity) measure (R) for continuous variables such as
gene expression data.
where   is the standard
covariance and   is the vari-
ance. Based on this definition we have R(x, y) = R(y, x),
and R = 0 when x and y are independent and R ≥ 1, when
either var(x) ≤ cov(x, y) or var(y) ≤ cov(x, y). It is clear that
this definition of R is different from the standard correla-
tion coefficient   in its
denominator. However, R can catch the the genes that
have very small changes in expression but are highly cor-
related with the significantly expressed (downstream)
genes. For instance, given cov(x, y) = 0.01, var(x) = 0.01,
and var(y) = 1, we have both R = 1 and r = 0.1. Our defi-
nition of R guarantees that the upstream regulatory genes
and the downstream genes will be in the same group.
The Integrated Algorithm
We now incorporate the correlation structure into the
gene selection and pathway identification algorithm.
Given a set of n independent observations  :
1. The gene selection step: Identifying a small subset of
individual genes that are associated with cancer using Lp
regularized Bayesian logistic regression
2. For each selected gene xi, find all xj from the original
data set, such that |R(xi, xj)| ≥ h, where h is a threshold and
set to 0.9 for experiments in this paper.
3. For each subset of selected genes, identify the pathways
associated with it using DAVID.
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